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PREVALENCE AND CLINICAL CHARACTERISTICS OF ELEVATED  
1Α,25-DIHYDROXYVITAMIN D IN PEDIATRIC NEPHROLITHIASIS  
AND RELATED DISORDERS 
JENNIFER DRUCKER 
ABSTRACT 
Introduction: The incidence of pediatric nephrolithiasis (kidney stones) has been 
increasing over the past several years. While environmental factors, such as poor fluid 
intake, high-salt diet, and obesity, can play a role, underlying metabolic factors account 
for at least one-third of cases of nephrolithiasis. Nephrolithiasis and related disorders, 
such as nephrocalcinosis and hypercalciuria, can lead to long-term kidney problems, 
including renal scarring, acute and chronic kidney disease, decreased renal function, or 
end-stage renal disease. The best treatment is prevention and is best guided by knowing 
the underlying cause. The majority of kidney stones are primarily comprised of calcium, 
and abnormal calcium metabolism and regulation can lead to nephrolithiasis, 
nephrocalcinosis, and hypercalciuria.  
 Vitamin D is an important factor in calcium regulation in the body. The 
physiologically active form of vitamin D is 1α,25-dihydroxyvitamin D (1,25(OH)2D), 
which increases serum calcium by stimulating intestinal absorption of calcium, increasing 
renal calcium reabsorption, and mobilizing calcium from bone. Excess 1,25(OH)2D has 
been shown to be associated with hyperabsorption of calcium in the intestine, 
nephrolithiasis, hypercalcemia, and hypercalciuria.  
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 Production of 1,25(OH)2D requires hydroxylation of 25-hydroxyvitamin D by the 
kidney enzyme 1α-hydroxylase, which is regulated in turn by serum calcium, parathyroid 
hormone (PTH), and by 1,25(OH)2D itself. Tight control of 1,25(OH)2D levels is 
maintained in part by the breakdown of 1,25(OH)2D by the enzyme 24-hydroxylase, 
which is encoded by the gene CYP24A1. In the past few years, CYP24A1 mutations 
leading to decreased activity of 24-hydroxylase have been implicated in some cases of 
idiopathic infantile hypercalcemia as well as nephrolithiasis, nephrocalcinosis, and 
hypercalciuria.  
 The prevalence of 24-hydroxylase deficiency is not known, and the spectrum of 
its clinical manifestations is not yet fully understood. Our study aims to describe the 
clinical characteristics of patients with laboratory findings suggestive of 24-hydroxylase 
deficiency, specifically high-normal or elevated serum 1,25(OH)2D. We aimed to 
determine the prevalence of elevated 1,25(OH)2D among pediatric patients with 
nephrolithiasis, and to compare clinical outcomes and biochemical findings in patients 
with normal versus elevated 1,25(OH)2D.  
 
Patients and Methods: This study was a retrospective chart review. To determine the 
prevalence of high-normal (56-75 pg/mL) and high (>75 pg/mL) serum 1,25(OH)2D, we 
reviewed electronic medical records of patients seen in the Boston Children’s Hospital 
Stone Clinic. We identified 346 patients who were evaluated for nephrolithiasis, were 
under 18 years of age at the time of presentation, and had at least one measurement of 
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1,25(OH)2D. Patients were classified based on their highest measured level of 
1,25(OH)2D.  
 To determine the clinical characteristics of patients with elevated 1,25(OH)2D, we 
reviewed clinical records and laboratory data of patients at Boston Children’s Hospital 
with a diagnosis of nephrolithiasis, nephrocalcinosis, or hypercalciuria. We identified 83 
patients who met our inclusion criteria: age of onset <18 years, at least one measurement 
of 1,25(OH)2D, and a pre-treatment urine solute analysis. Data collected included 
demographic information, diagnoses, family history of kidney disease, treatments, 
laboratory data, and urine solute analyses. We compared findings in patients with normal 
1,25(OH)2D (≤55 pg/mL) versus elevated 1,25(OH)2D (>55 pg/mL).  
 
Results: Of 346 children with nephrolithiasis in whom 1,25(OH)2D was measured, 100 
(28.9%) had high 1,25(OH)2D, and an additional 120 (34.7%) had high-normal 
1,25(OH)2D. To determine the clinical characteristics of elevated 1,25(OH)2D, we 
analyzed the data of 40 patients with normal 1,25(OH)2D and 43 patients with elevated 
1,25(OH)2D who had a history of nephrolithiasis, nephrocalcinosis, or hypercalciuria. 
Seventy-five children had nephrolithiasis, and 25/37 (67.6%) of children with elevated 
1,25(OH)2D had a recurrence of nephrolithiasis, compared to only 9/38 (23.7%) of 
children with normal 1,25(OH)2D (p < .001). Urine calcium/creatinine ratio did not differ 
between the two groups. However, linear regression analysis showed an association 
between 1,25(OH)2D levels and urine calcium/creatinine ratio. Important secondary 
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findings included a younger age of onset, higher serum 25-hydroxyvitamin D, and lower 
parathyroid hormone levels in patients with elevated 1,25(OH)2D.  
 
Conclusions: Important clinical findings of this study were the increased rate of 
recurrence and the younger age of onset in patients with elevated 1,25(OH)2D. While we 
recognize that mutations in CYP24A1 do not account for the majority of cases of elevated 
1,25(OH)2D, we do advocate for special consideration for these patients. In the absence 
of a commercially-available assay for 24-hydroxylase activity, children with 
nephrolithiasis, nephrocalcinosis, or hypercalciuria and elevated 1,25(OH)2D should be 
closely monitored for recurrence or worsening of symptoms. Furthermore, we advise 
caution in the use of vitamin D repletion in at-risk patients. 
  
  x
TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……………………………………………………………………...ii 
READER APPROVAL PAGE…………………………………………………………..iii 
DEDICATION ................................................................................................................... iv 
ACKNOWLEDGMENTS .................................................................................................. v 
ABSTRACT ....................................................................................................................... vi 
TABLE OF CONTENTS .................................................................................................... x 
LIST OF TABLES ............................................................................................................. xi 
LIST OF ABBREVIATIONS ........................................................................................... xii 
INTRODUCTION .............................................................................................................. 1 
SPECIFIC AIMS .............................................................................................................. 22 
PATIENTS AND METHODS .......................................................................................... 23 
RESULTS ......................................................................................................................... 28 
DISCUSSION ................................................................................................................... 33 
REFERENCES ................................................................................................................. 42 
CURRICULUM VITAE ................................................................................................... 47 
 
  
  xi
LIST OF TABLES 
 
 
Table Title Page 
1 Vitamin D (1,25(OH)2D) levels in pediatric patients with 
nephrolithiasis 
 
28 
2 Demographics and clinical characteristics of patients with 
normal (≤55 pg/mL) versus elevated (>55 pg/mL) 
1,25(OH)2D 
 
29 
3 Analysis of clinical variables predicting recurrence of 
nephrolithiasis 
 
30 
4 Laboratory Data 31 
5 Analysis of clinical variables predicting urine Ca/Cr ratio 32 
 
 
 
  
  xii
LIST OF ABBREVIATIONS 
 
1,25(OH)2D ................................................................................. 1α,25-dihydroxyvitamin D 
25(OH)D ............................................................................................. 25-hydroxyvitamin D 
APRTD ....................................................... Adenine phosphoribosyltransferase deficiency 
BCH ........................................................................................... Boston Children’s Hospital 
Ca/Cr .............................................................................................. Calcium/Creatinine ratio 
CKD ................................................................................................. Chronic kidney disease 
DBP ............................................................................................. Vitamin D binding protein 
ESRD ............................................................................................... End-stage renal disease 
ESWL ........................................................................Extracorporeal shock wave lithotripsy 
GFR ............................................................................................... Glomerular filtration rate 
IIH ................................................................................... Idiopathic infantile hypercalcemia 
IOM ...................................................................................................... Institute of Medicine 
IU .............................................................................................................. International Unit 
NHANES ............................................. National Health and Nutrition Examination Survey 
NLRP3 ........................ NOD-like receptor, leucine-rich repeat, pyrin-domain containing 3 
PCNL ....................................................................................Percutaneous nephrolithotomy 
PTH ...................................................................................................... Parathyroid hormone 
RDA ................................................................................. Recommended dietary allowance 
 
 1 
INTRODUCTION 
 
 Kidney stones, or nephrolithiasis, are a disease of the urinary tract in which 
crystals aggregate to form mineral deposits within the kidney. There are several 
metabolic causes for nephrolithiasis as well as contributing environmental factors, 
including low fluid intake, high salt intake, and obesity. Calcium nephrolithiasis may be 
seen in conjunction with increased urine calcium crystals in the kidney. Over the past 
several years, there has been an increase in the incidence of nephrolithiasis in 
industrialized countries (Milliner, 2009), with a current lifetime prevalence of 
nephrolithiasis estimated between estimated between 10-15%, dependent upon age, sex, 
race, and geographic location (Nesterova et al., 2013). In addition to the acute, severe 
pain described by many stone patients, the formation of crystals and stones, passage of 
stones, and treatment can cause long-term damage, including chronic kidney disease 
(CKD) and renal scarring. Moreover, the overall recurrence rate of kidney stones is 
estimated to be 20-40% and is especially high in children with a metabolic basis for stone 
formation (Milliner, 2009).  
 
Incidence and Epidemiology 
 In a report from the 2007-2010 National Health and Nutrition Examination 
Survey (NHANES), Scales et al. found an 8.4% population-adjusted prevalence of 
nephrolithiasis in adults in the United States, a significant increase from the NHANES 
estimated prevalence of 5.2% in 1994 (Scales, Smith, Hanley, Saigal, & Urologic 
Diseases in America Project, 2012). The incidence of nephrolithiasis increases with age 
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(Milliner, 2009; Sas, Hulsey, Shata t, & Orak, 2010; Scales et al., 2012). Adults ages 60-
69 are at the highest risk with a prevalence of 14.3% (Sas et al., 2010).  
 In the United States, pediatric nephrolithiasis accounts for 0.1-1.3% of 
hospitalizations of children and adolescents, a number that is less than 2% of the reported 
adult rate (Milliner, 2009). Like adult nephrolithiasis, pediatric nephrolithiasis appears to 
be increasing in incidence. VanDervoort et al. conducted a retrospective chart review of a 
single center over two time periods, 1994-1996 and 2003-2005 (VanDervoort et al., 
2007). Adjusting for the number of new visits, they report a 4-fold increase in the number 
of new cases of nephrolithiasis in children between the two periods. Sas et al. (2010) 
conducted a study of the incidence of pediatric nephrolithiasis in South Carolina 
emergency departments between 1996 and 2007 and found an overall incidence of 12.0 
per 100,000 children in the 12-year period. There were 8.1 diagnoses of nephrolithiasis 
per 100,000 visits to the emergency department in 1996. This number rose steadily to 
13.9 per 100,000 in 2007.  
 The higher rate of diagnosis of pediatric nephrolithiasis may be in part due to 
increased use of radiographic techniques, such as ultrasound and CT, resulting in more 
incidental findings of nephrolithiasis (Milliner, 2009; VanDervoort et al., 2007). It may 
also be attributed in small part to the longer survival of patients with childhood diseases 
that are associated with nephrolithiasis. In addition, increased awareness and 
consideration of the diagnosis in a child with colicky abdominal pain may also play a 
role.  
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 There are many factors that contribute to lifetime risk of stone development. 
Historically, men have had a higher prevalence of stone disease than women. In the 2007-
2010 NHANES, the estimated prevalence was higher for men than women in a 1.5:1 ratio 
(Scales et al., 2012). However, this does not appear to hold true for pediatric 
nephrolithiasis. Sas et al. (2010) found a higher prevalence of nephrolithiasis among girls 
than boys, especially in adolescents. Furthermore, while girls account for only 46% of 
pediatric hospitalizations overall, they accounted for 56% of hospitalizations for 
nephrolithiasis and 61% of readmissions between 2002 and 2007 (Bush et al., 2010; Sas, 
2011). The only adult age group for whom prevalence was higher in women was 20 to 29 
years (Sas, 2011). The reasons for this discrepancy are not yet understood, although 
frequent urinary tract infections (UTIs) are implicated as a contributing factor.  
 Environmental factors likely play a role in the risk for stone formation. National 
data show an increased prevalence of kidney stones in the southeastern region of the 
United States in what is known as the “Stone Belt” (Milliner, 2009; Sas et al., 2010). This 
regional difference may be due to higher temperatures leading to dehydration, which is 
supported by the higher incidence of nephrolithiasis in the summer months, or due to 
dietary factors such as a high-salt diet (Sas et al., 2010). However, the full cause is not 
understood. Additionally, socioeconomic standing seems to play a role, with the highest 
prevalence of stone disease in individuals with the lowest household income (Scales et 
al., 2012). This may again be related to dietary factors, such as a high-salt diet, or to 
obesity.  
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Signs and Symptoms 
 Although some patients may present with gross hematuria, the most common 
symptom associated with nephrolithiasis is extreme pain (renal colic). However, renal 
colic as the primary symptom of nephrolithiasis is highly age-dependent. While 94% of 
adolescents complain of flank or abdominal pain at presentation, the number drops to 
72% in school-age children and only 56% in children ages zero to five (Milliner, 2009). 
Younger children may report abdominal pain rather than renal colic, or they may be 
unable to clearly articulate what is bothering them (VanDervoort et al., 2007). 
Approximately half of patients with nephrolithiasis under five years of age are diagnosed 
during evaluation for urinary tract infection or via an incidental radiographic finding 
(Milliner, 2009). This means that without screening, pediatric nephrolithiasis may remain 
undiagnosed until later in life, leading to potential injury to the kidneys and urinary tract 
before a diagnosis is made.  
 
Pathophysiology 
 The majority of urinary tract stones originate in the kidney, and 60-78% of stones 
are still present in the kidney at the time of diagnosis (Milliner, 2009). The majority of 
stones found in the ureters and bladder at the time of diagnosis originate in the kidneys. 
Approximately 10% of stones originate in the bladder and are believed to be primarily 
caused by dietary factors. Most stones are chemically comprised of calcium. Forty to 
sixty percent are calcium oxalate, 15-25% are calcium phosphate, and 10-25% are mixed 
calcium phosphate and calcium oxalate. 
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 There are many causes of nephrolithiasis. Metabolic causes and structural 
abnormalities of the urinary tract are the most common, causing 33% and 32% of stones, 
respectively (Milliner, 2009). However, the proportion of metabolic causes may be 
underrepresented due to incomplete metabolic workup in some patients. In one study 
cohort in whom a full metabolic evaluation was performed, a metabolic basis for stones 
was found in 53% of patients (Noe, Stapleton, Jerkins, & Roy, 1983). There is also strong 
evidence for a genetic basis of abnormal calcium metabolism among stone formers. Forty 
to forty-five percent of patients with idiopathic hypercalciuria have at least one family 
member with nephrolithiasis (Dinour et al., 2013), and approximately 40% of stone 
formers report a family history of nephrolithiasis (Nesterova et al., 2013). Although the 
precise genetic factors associated with calcium-based nephrolithiasis are mostly 
unknown, they are believed to be associated with increased intestinal calcium absorption, 
renal reabsorption, and bone resorption (Dinour et al., 2013).  
 
Related Disorders 
 Unsurprisingly, nephrolithiasis is often related to other urinary calcium disorders, 
including hypercalciuria and nephrocalcinosis. Pediatric hypercalciuria is defined as a 
urine excretion greater than 4 mg/kg/day or a urinary calcium/creatinine (Ca/Cr) ratio 
greater than 0.21 mg/mg in patients over 2 years of age (Milliner, 2009; Stapleton, 1990). 
In children under 2 years of age, urine calcium excretion is greater, and a urine Ca/Cr 
ratio up to 0.8 mg/g may be normal. A prospective study of 184 children with 
microscopic hematuria found that 60 children had hypercalciuria, of whom eight (13%) 
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developed nephrolithiasis during a 1- to 4-year follow-up period (Stapleton, 1990). An 
earlier retrospective study of 68 children with hypercalciuria found that 49 children 
(72%) developed nephrolithiasis during a follow-up period of 2 to 15 years (Turi et al., 
1989). Approximately 50-60% of stone formers are found to have hypercalciuria (Dinour 
et al., 2013; Nesterova et al., 2013), in contrast to 5-10% of healthy children (Milliner, 
2009).  
 Nephrocalcinosis is a diffuse deposition of calcium salts in the renal parenchyma, 
most commonly in the medullary pyramids. Nephrocalcinosis has many of the same risk 
factors and physiological mechanisms as nephrolithiasis (Milliner, 2009). Because mild 
nephrocalcinosis is often asymptomatic, the overall prevalence is not well known 
(Nesterova et al., 2013), but it occurs more often in infants and young children (Milliner, 
2009). When not accompanied by nephrolithiasis, nephrocalcinosis often occurs with 
hypercalciuria or hyperoxaluria and is more likely to be associated with loss of renal 
function.  
 
Prognosis 
 In general, stones under 5 mm in diameter are often passed in the urine, but 
passage of a stone may lead to scarring in the kidney, ureters, and urethra (Milliner, 
2009). Stones that do not pass may grow in size and lead to obstruction of the urinary 
tract. If the obstruction is not relieved, it can lead to dilatation of the urinary collecting 
system due to obstruction (hydronephrosis), thinning of the renal cortex, and impaired 
renal function. Large stones may need intervention, such as extracorporeal shock wave 
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therapy (ESWL), ureteroscopic lithotripsy and/or removal, percutaneous stone removal 
(PCNL), or, in rare cases, open lithotomy. Each intervention entails a risk of damaging 
renal tissues. The risk of renal insufficiency among patients with idiopathic calcium 
oxalate nephrolithiasis is 1.7% (Milliner, 2009).  
 The long-term effects of nephrocalcinosis vary widely. In some cases, it remains 
asymptomatic and causes no problems with renal function. In others, it can lead to acute 
and chronic kidney injury, decreased renal growth, CKD, and, in some cases, end-stage 
renal disease (ESRD) (Milliner, 2009).  
 Hypercalciuria has been targeted as a cause for renal scarring in patients with 
nephrolithiasis and hypercalciuria due to both direct effects of urinary crystals and 
resulting inflammatory responses. Animal models have shown that inflammatory markers 
such as the NOD-like receptor, leucine-rich repeat, pyrin-domain containing 3 (NLRP3) 
may explain the inflammatory mechanism of crystal-mediated nephropathy (Knauf et al., 
2013; Lorenz, Darisipudi, & Anders, 2014). In other crystallopathies such as gout and 
atherosclerosis, inflammation involved the secretion of IL-1β via the NLRP3/apoptosis-
associated speck-like protein containing CARD/caspase-1 axis (Mulay et al., 2013). 
Calcium oxalate crystals activate the same pathway by acting as damage-associated 
molecular patterns (DAMPs), resulting in damage to the tubules and renal parenchyma in 
hypercalciuria as well as nephrocalcinosis (Lorenz et al., 2014; Mulay et al., 2013).  
 The cause of nephrolithiasis may affect the prognosis. Some diseases, such as 
Dent’s disease (which is associated with hypercalciuria), primary hyperoxaluria, and 
adenine phosphoribosyltransferase deficiency (APRTD), put patients at an increased risk 
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for significant nephrolithiasis or nephrocalcinosis (Milliner, 2009). Because of the renal 
damage caused by urinary calcium disorders, the best treatment is prevention, through 
both dietary and pharmacological interventions.  
 
Calcium Homeostasis 
Because calcium is important for many physiological functions- including muscle 
contraction, blood coagulation, nerve conduction, and bone mineralization- calcium 
homeostasis must be tightly regulated. Low serum calcium (hypocalcemia) or high serum 
calcium (hypercalcemia) can have severe negative effects including seizures, cardiac 
arrhythmias, or death. 
Most calcium in the body is stored in bone as hydroxy-apatite crystals (Portale & 
Perwad, 2009; Portale & Perwad, 2009) . A small amount exists in a rapidly exchanging 
pool between bone and plasma and contributes to the physiological effects of calcium. 
Healthy adults maintain a zero balance of calcium, that is, calcium intake is equivalent to 
calcium excretion. In contrast, in growing children a net daily retention of calcium of 
150-200 mg supports skeletal growth. Calcium homeostasis is maintained by actions 
primarily within the intestine, kidneys, and bone. Healthy adults absorb 20-25% of 
ingested calcium. Intestinal calcium absorption occurs primarily in the duodenum and 
proximal jejunum through both passive diffusion and by a saturable active transport 
mechanism stimulated by vitamin D. Ionized and complexed calcium account for 60% of 
plasma calcium and are freely filtered by the glomerulus. About 98-99% of this is 
reabsorbed, or approximately 8 gm/day, primarily in the proximal tubule. There does not 
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appear to be a maximum tubular reabsorptive rate (Tm) for calcium within the normal 
physiologic range (Portale & Perwad, 2009). 
Calcium homeostasis is regulated primarily by parathyroid hormone (PTH) and 
vitamin D. Both are stimulated by low plasma calcium and act to increase the absorption 
and resorption of calcium. PTH stimulates osteoclast activity to release calcium from 
bone. It is also the primary determinant of renal calcium reabsorption both by stimulating 
renal reabsorption directly and by partially reducing excretion by decreasing the 
glomerular filtration rate (GFR). Vitamin D plays a secondary role by promoting renal 
reabsorption at the distal tubule.  Vitamin D also stimulates intestinal calcium absorption 
via a saturable active transport mechanism. 
Disorders of either PTH or vitamin D metabolism may cause nephrolithiasis, 
nephrocalcinosis, and hypercalciuria. Hyperparathyroidism, which results in excess PTH, 
is known to mobilize too much calcium from bone and increase renal reabsorption, 
leading to hypercalcemia, hypercalciuria, and nephrolithiasis. Vitamin D has long been 
implicated in hyperabsorptive hypercalciuria and nephrolithiasis. The direct relationship 
between vitamin D and intestinal absorption of calcium is exaggerated in hyperabsorptive 
nephrolithiasis (Alvarez-Arroyo, Traba, Rapado, de la Piedra, & Torralbo, 1992). It is 
this hyperabsorptive calcium excess on which our study is focused. 
 
Vitamin D 
 The clinical benefits of vitamin D have been well-established in particular for the 
treatment of vitamin D-deficient rickets (Samuel, 1964; Schlingmann et al., 2011). It is 
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also useful for the prevention of osteoporosis. While beneficial effects of vitamin D for 
cardiovascular health and the prevention of neoplastic disease have been suggested (Leaf 
et al., 2012), the association has yet to be proven and is highly debated (Manson & 
Bassuk, 2015).  
  
Metabolism, Regulation, and Action 
 Vitamin D is produced primarily in human skin cells by the action of UVB 
radiation on 7-dehydrocholesterol (Institute of Medicine, 2011; Mugg et al., 2015; Portale 
& Perwad, 2009). Vitamin D3 is an inactive pro-hormone that is activated by consecutive 
hydroxylation by multiple cytochrome P450 enzymes. Vitamin D is first hydroxylated in 
the liver by CYP2R1 (and possibly CYP27A1) to form 24-hydroxyvitamin D (25(OH)D) 
(Institute of Medicine, 2011; Mugg et al., 2015; Portale & Perwad, 2009; Wolf et al., 
2014). This step is not tightly regulated, and has little, if any feedback regulation. 
25(OH)D levels are therefore highly dependent on sunlight exposure and dietary intake. 
 25(OH)D is converted to the physiologically active form, 1α,25-dihydoxyvitamin 
D (1,25(OH)2D) by the enzyme 25-hydroxyvitamin-D-1α-hydroxylase (1α-hydroxylase, 
CYP27B1), primarily in the kidneys. There is evidence to suggest that CYP27B1 also has 
function in other tissues including keratinocytes, lungs, macrophages, brain, testes, and 
osteoblasts (Mugg et al., 2015; Prosser & Jones, 2004).  
 Both 25(OH)D and 1,25(OH)2D are inactivated by the action of the enzyme 24-
hydroxyvitamin-D-24-hydroxylase (24-hydroxylase, CYP24A1) (Portale & Perwad, 
2009; Prosser & Jones, 2004; St-Arnaud, 1999). CYP24A1 is expressed in most, if not 
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all, vitamin D target tissues, though the main sites of vitamin D inactivation are the 
kidney and liver (Portale & Perwad, 2009). CYP24A1 catalyzes the breakdown of 
1,25(OH)2D to calcitroic acid and of 25(OH)2D to 24,25-dihydroxyvitamin D 
(24,25(OH)2D), both of which are inactive.  
 1α-hydroxylase activity is stimulated by PTH and by phosphorus deficiency to 
increase phosphorus absorption in the intestine (Portale & Perwad, 2009). Conversely, 
enzyme activity is suppressed by high serum levels of calcium, by fibroblast growth 
factor 23 (FGF-23), and by 1,25(OH)2D itself via a negative regulatory vitamin D 
response element (VDRE) upstream of the CYP27B1 promotor region (Prosser & Jones, 
2004). Increased levels of 1,25(OH)2D also induce expression of CYP24A1, leading to 
vitamin D catabolism (Portale & Perwad, 2009). In the kidney, PTH suppresses 
CYP24A1 expression, thus increasing renal reabsorption of calcium in the distal tubule 
via high levels of 1,25(OH)2D. However, in osteoblasts, PTH enhances 1,25(OH)2D-
mediated induction of CYP24A1 in order to prevent sudden spikes in 1,25(OH)2D and 
resultant bone formation abnormalities (Jones, Prosser, & Kaufmann, 2012).  
 One of the most important actions of vitamin D is to maintain calcium balance. 
1,25(OH)2D increases serum calcium and phosphate primarily by increasing intestinal 
absorption. It plays a minor role in mobilizing calcium from bone and renal reabsorption 
of calcium and phosphate. 1,25(OH)2D is the most important stimulus for intestinal 
calcium absorption, which it achieves by stimulating synthesis of the epithelial calcium 
channel TRPV6, calbindin 9, and the calcium adenosine triphosphatase pump (Nesterova 
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et al., 2013). By similar mechanisms, 1,25(OH)2D stimulates reabsorption of calcium in 
the kidney.  
 
Clinical Uses of Vitamin D 
 Vitamin D supplementation is routinely advocated, especially among pediatric 
and geriatric patient populations, to promote bone health, although there continues to be 
debate about the recommended dietary allowance (RDA). Currently, the Institute of 
Medicine (IOM) recommends 400 IU per day for infants, 600 IU per day for people ages 
1 to 70 years and 800 IU per day for people over 70 years of age, which can be achieved 
through the consumption of fortified foods or over-the-counter supplements (Institute of 
Medicine, 2011; Manson & Bassuk, 2015).  
A benefit of dietary supplementation of vitamin D is its wide therapeutic window. 
However, even in healthy patients, excess vitamin D can lead to toxicity due to severe 
hypercalcemia. Symptoms of vitamin D toxicity (hypervitaminosis D) include thirst, 
itchiness, diarrhea, general malaise, polyuria, and diminished appetite (Blank, Scanlon, 
Sinks, Lett, & Falk, 1995; Deluca, Prahl, & Plum, 2011). In severe cases, calcifications 
may be found in the kidneys, aorta, heart, lung, and subcutaneous tissues, and renal 
failure or death can result. Two early reports of infant vitamin D fatalities were linked to 
extreme vitamin D dosages, with a daily administration of 30,000-40,000 IU over a 
course of 8-12 months (Ketha, Wadams, Lteif, & Singh, 2015). Between 1988 and 1991, 
eight patients in the greater Boston area were diagnosed with vitamin D toxicity due to 
overfortification of milk from a local dairy (Blank et al., 1995). It was found that the 
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samples from the dairy contained between 70 to 600 times the state limit of 500 IU per 
quart. 
 The precise mechanism of vitamin D toxicity is unclear. Hypotheses include 
increased production of 1,25(OH)2D or overwhelming of the binding capacity of vitamin 
D binding protein (DBP), thus releasing excess 1,25(OH)2D to enter target cells (Ketha et 
al., 2015). However, both of these hypothesis were called into question by studies of 
Cyp27b1-/- knockout mice (Deluca et al., 2011). Cyp27b1-/- and wild type mice both had 
similar reactions to high doses of 25(OH)D. Because the Cyp27b1-/- mice cannot produce 
1,25(OH)2D, this implicates 25(OH)D as the primary metabolite responsible for vitamin 
D toxicity in otherwise healthy patients. An alternate hypothesis for the mechanism of 
vitamin D toxicity is that high doses over 25(OH)D overwhelm the DBP binding 
capacity, allowing for excess 25(OH)D in the plasma to exert a direct effect on target 
cells at extremely high serum concentrations (Ketha et al., 2015).  
 While 25(OH)D appears to be a culprit for vitamin D toxicity in otherwise healthy 
patients, patients with certain lymphomas and granulomatous diseases demonstrate 
symptoms of vitamin D toxicity that has been shown to be associated with elevated 
1,25(OH)2D. In recent years, elevated serum 1,25(OH)2D has been implicated in several 
cases of idiopathic infantile hypercalcemia, nephrolithiasis, and nephrocalcinosis 
(Castanet, Mallet, & Kottler, 2013; Dauber et al., 2012; Dinour et al., 2013; Dowen, 
Sayers, Hynes, & Sayer, 2014; Fencl, Blahova, Schlingmann, Konrad, & Seeman, 2013; 
Jacobs et al., 2014; Meusburger et al., 2013; Nesterova et al., 2013; Schlingmann et al., 
2011; Skalova et al., 2013; Streeten, Zarbalian, & Damcott, 2011; Wolf et al., 2014).  
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Vitamin D Supplementation and Idiopathic Infantile Hypercalcemia 
 In 1943, the British Paediatric Associated recommended vitamin D 
supplementation for the general population to help prevent rickets (Samuel, 1964). 
Nationwide efforts led to the fortification of milk, infant cereals, and cod-liver oil 
compounds to aid in providing children with the recommended dose of up to 4,000 IU of 
vitamin D daily (Schlingmann et al., 2011). In the early 1950s, Great Britain saw a spike 
in cases of infantile hypercalcemia with nephrocalcinosis with no known origin, first 
described by R. Lightwood as idiopathic infantile hypercalcemia (IIH). Between January 
1953 and June 1955, there were 216 reported cases of IIH, or 7.2 per month. Meanwhile, 
in the United States, where vitamin D supplementation was 10-25% of the dosage 
recommended in Great Britain, there were only 10 reported cases of IIH (Schlingmann et 
al., 2011). In 1957, the Ministry of Health suggested a reduction by half of the amount of 
supplemental vitamin D given to infants (Samuel, 1964). Between January 1960 and May 
1961, the reported number of cases of IIH dropped to 50, or 3.0 per month. While a 
causative link was not established, a correlation was strongly implied. Importantly, only 
some patients manifested with IIH, despite national vitamin D fortification, suggesting a 
hypersensitivity to vitamin D in certain individuals. While some cases of IIH could later 
be explained by other disorders, such as Williams-Beuren syndrome, thyroid or adrenal 
disorders, disordered bone metabolism, or subcutaneous fat necrosis, others still remained 
unexplained (Castanet et al., 2013; Nguyen et al., 2010).  
 15 
 It was later found that some patients with IIH may have had increased 
1,25(OH)2D and suppressed PTH, suggesting a problem with 1,25(OH)2D regulation 
(Dauber et al., 2012; Schlingmann et al., 2011; Scott et al., 1998). Activating mutations 
in CYP27B1 were postulated, but Scott et al. (1998) were unable to find evidence of 
these. However, the fact that ketoconazole, and inhibitor of cytochrome P450 enzymes, 
was useful in treating IIH served as strong indication that IIH might be caused by 
problems with 1,25(OH)2D metabolism. Schlingmann et al. (2011) studied six patients 
from four families with IIH and four additional patients who suffered vitamin D 
intoxication and hypercalcemia after prophylactic vitamin D pulse therapy.  All 10 
patients were found to have either homozygous or compound heterozygous mutations of 
CYP24A1, the gene encoding 24-hydroxylase. Furthermore, while healthy patients 
maintain stable levels of 1,25(OH)2D after a bolus of 25(OH)D due to tight regulation, 
patients with IIH were found to have spikes in 1,25(OH)2D, indicating impaired 
catabolism. A concurrent study by Dauber et al. (2012) confirmed that hypercalcemia is 
due to calcium hyperabsorption in the gut via calcium isotope studies, suggesting the 
underlying mechanism. However, they looked specifically at a cohort of patients with IIH 
and found no other CYP24A1 mutations, suggesting that this is one cause for IIH, but a 
rare one. The studies by Schlingmann et al. and Dauber et al. provided strong evidence 
for mutations in CYP24A1 as the basis of certain cases of IIH and suggested a role of 
CYP24A1 mutations in other disorders of calcium excess.  
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CYP24A1 
Structure and Action 
 The enzyme 24-hydroxylase is responsible for the inactivation and degradation of 
both 25(OH)D and 1,25(OH)2D. It is comprised of three components: ferredoxin, 
ferredoxin reductase, and a cytochrome P450. Of these, only the cytochrome P450 
element, CYP24A1, is specific to the 24-hydroxylation of vitamin D (Jones et al., 2012). 
The enzyme contains 514 amino acids (Nesterova et al., 2013) in a highly evolutionarily 
conserved sequence across 57 species from bony fish to man (Jones et al., 2012). Nearly 
the entire protein is required to maintain the structure, heme-binding, and activity. While 
the crystal structure of human CYP24A1 has yet to be reported, its DNA sequence shares 
82% identity and 90% similarity with rat CYP24A1, the structure of which has been 
reported (Mugg et al., 2015). Rat CYP24A1 shows the canonical cytochrome P450 
structure of helices and β-pleated sheets surrounding a prosthetic heme group and a 
substrate binding pocket (Jones et al., 2012).  
 CYP24A1 is found in the mitochondria of vitamin D target tissues, especially 
kidneys, intestine, bone, and skin (Masuda et al., 2005). It is one of 60 known 
cytochrome P450s and one of four vitamin D-related cytochrome P450s, alongside 
CYP27A1, CYP2R1, and CYP27B1. However, while each of three catalyzes only one 
step in vitamin D metabolism, CYP24A1 catalyzes several different steps and side 
reactions. Its most important function is to catalyze the five-step breakdown of 
1,25(OH)2D to calcitroic acid, an inactive water-soluble product that is excreted in bile. 
1,25(OH)2D is the preferred substrate of CYP24A1 and upregulates expression of the 
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enzyme in order to attenuate its own action. 25(OH)D is converted by CYP24A1 to 
24,25-dihydroxyvitamin D (24,25(OH)2D), a metabolite with negligible physiological 
function (St-Arnaud et al., 2000). Thus, CYP24A1 modulates vitamin D action by 
inactivating its two most common forms.  
 
In vitro Studies 
 To study the role of CYP24A1 in vitamin D metabolism, St-Arnaud et al. 
developed a line of 24-hydroxylase knockout mice (Cy24a1-/-) (St-Arnaud, 1999). Of 
these, 49% were dead due to hypercalcemia at weaning, showing significant perinatal 
lethality. The animals that survived were unable to effectively clear 1,25(OH)2D, with 
levels that remained abnormally elevated hours to days after a bolus of vitamin D. 
Furthermore, offspring of homozygous mutant females had mineralization defects and 
incomplete mineralization at sites of intramembranous ossification, a finding later 
attributed to elevated levels of 1,25(OH)2D in the mother (St-Arnaud et al., 2000). Long-
term vitamin D treatment of knockout mice led to renal calcium deposition consistent 
with nephrocalcinosis.  
 A related study of Cyp24a1-/- knockout mice by Masuda et al. (2005) 
supplemented the findings by St-Arnaud et al. In the study, homozygous mutants were 
unable to completely clear exogenous 1,25(OH)2D after 96 hours, with levels that 
remained 20- to 30-fold higher than in their heterozygous Cyp24+/- littermates. Levels of 
1,25(OH)2D were especially high in the kidneys, indicating a lack of homeostasis in a 
target tissue. Serum tests of Cyp24a1-/- mice showed a lack of 24-hydroxylated 
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metabolites and the side product 1α,25(OH)2D-26,23-lactone, despite having sufficient 
substrate for enzyme activity. Comparative in vitro studies of CYP24A1 activity in 
mouse keratinocytes demonstrated an absence of the enzyme products in Cyp24a1-/- 
mouse cells.  
 
Reported Mutations in CYP24A1 
 Since the initial description of CYP24A1 mutations as a cause of IIH, there have 
been a total of 18 distinct mutations reported in case studies across 25 symptomatic and 3 
asymptomatic patients (Figueres et al., 2015), reviewed in (Mugg et al., 2015). Among 
these, E143del, L409S, R396W, E22K, and E151X have been reported in multiple 
patients. While some mutations correlate with mild disease, such as asymptomatic 
nephrocalcinosis, others have been implicated in more severe disease including IIH and 
recurrent nephrolithiasis, demonstrating the variability of phenotypes in CYP24A1 
mutations (Mugg et al., 2015).  
 In vitro mutations of CYP24A1 led to ablation of CYP24A1 catabolic activity in 
most tested mutations (Schlingmann et al., 2011). The exception was L409S, which 
maintains 32% of wild-type activity (Mugg et al., 2015). Leucine 409 is not part of the 
substrate binding pocket, substrate access channel, or redox partner binding site, and the 
L409S mutation most likely affects protein conformation by substituting a polar residue 
for an aliphatic one, thus affecting substrate binding.  
 In the initial report of CYP24A1 mutations related to IIH, Schlingmann et al. 
(2011) described four patients with IIH and 2 asymptomatic siblings with medullary 
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nephrocalcinosis. Four additional patients were identified who had vitamin D toxicity and 
severe hypercalcemia after receiving multiple large doses of vitamin D as prophylactic 
pulse therapy, the preferred method in the German Democratic Republic at the time. All 
symptomatic patients recovered with rehydration and cessation of vitamin D 
supplementation.  
 Multiple later case studies described patients with IIH and CYP24A1 mutations. In 
each case, the patients presented with dehydration and failure to thrive and were found to 
have high or high-normal 1,25(OH)2D and suppressed PTH (Castanet et al., 2013; 
Dauber et al., 2012; Ketha et al., 2015). Some patients were found to have the same 
mutations reported by Schlingmann et al., while others were found to have novel 
mutations. In each case, impaired activity of CYP24A1 was confirmed by measuring low 
levels of 24,25(OH)2D.  
 While infantile hypercalcemia is the most commonly reported presentation of 
CYP24A1 mutations, it is now apparent that symptoms may first appear later in life 
especially in milder phenotypes or in the absence of vitamin D supplementation. Older 
patients may first be identified due to nephrolithiasis or hypercalciuria rather than 
symptoms of hypercalcemia. In 2013, Nesterova et al. described two adult patients with 
elevated 1,25(OH)2D levels and inactivating mutations in CYP24A1 with no history of 
IIH as infants (Nesterova et al., 2013). One patient was diagnosed with nephrocalcinosis 
at the age of 3 during ultrasound for a urinary tract infection. The other was a 38-year-old 
man who had recurrent kidney stones starting at age 25. Dowen et al. (2014) described a 
man who first presented at age 10 and again at age 45 with kidney stones. Although he 
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was found to have the same homozygous E143del mutation as patients in the 2011 study, 
unlike the infants in the study by Schlingmann et al., this patient had never received 
vitamin D supplementation. This illustrates that, while vitamin D supplementation can 
lead to more severe problems with CYP24A1 mutations, it is not required for the 
manifestation of symptoms. Wolf et al. described a patient with recurrent nephrolithiasis 
and impaired calcium homeostasis who did not receive any vitamin D supplementation 
(Wolf et al., 2014). He was found to have two previously identified mutations in 
CYP24A1, and was described as having “late-onset idiopathic infantile hypercalcemia.” 
Recently, Mugg et al. described a 21-year-old male patient with bilateral nephrolithiasis, 
nephrocalcinosis, hypercalcemia, renal insufficiency with a creatinine level of 2 mg/L, 
and no detectable 24,25(OH)2D (Mugg et al., 2015). He took high doses of vitamin D and 
consumed 2-3 gallons of milk per week. The patient was found to have the missense 
mutation of CYP24A1 L409S on a single allele with no other identified mutations. 
Cessation of vitamin D supplementation and reduction of calcium intake were enough to 
return his calcium and creatinine levels to high normal.  
 The mode of inheritance of CYP24A1 mutations is not entirely agreed upon. Most 
studies have described autosomal recessive inheritance (Dauber et al., 2012; Dinour et al., 
2013; Nesterova et al., 2013; Schlingmann et al., 2011). However, Tebben et al. reported 
a splice site mutation believed to exhibit an autosomal dominant inheritance pattern with 
incomplete penetrance, thus accounting for variable phenotypes (Tebben et al., 2012).  
 Nesterova et al. (2013) sought to determine the risk of kidney stones related to 
CYP24A1 mutations, assuming an autosomal recessive pattern of inheritance. They found 
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13 deleterious mutations in dbSNP with a total minor allele frequency (MAF) of 0.140, 
or, disregarding one mutation with an especially high MAF, of 0.065. Applying these to 
the Hardy-Weinberg equation, they estimated the frequency of CYP24A1 mutations to be 
between 420 and 1960 per 100,000. Combined with a lifetime risk of stones estimated at 
10% for the general population, this leads to an estimated frequency of 4-20% of kidney 
stones due to CYP24A1 deficiency.    
 The spectrum of clinical manifestations of CYP24A1 mutations is not yet fully 
understood. While early studies focused on the relationship between mutations and 
CYP24A1 and IIH, later studies identified patients who had renal manifestations of 
disease, including nephrolithiasis, hypercalciuria, and nephrocalcinosis. Some patients 
with CYP24A1 mutations remained asymptomatic, and many became symptomatic only 
after vitamin D supplementation. There is a need for studies evaluating the prevalence of 
CYP24A1 mutations and the associated clinical characteristics in patients who do not 
present with idiopathic infantile hypercalcemia. Our study aims to address this issue by 
analyzing the prevalence and clinical characteristics of one of the most common 
characteristics of CYP24A1 mutations, specifically elevated 1,25(OH)2D, among 
pediatric patients with nephrolithiasis, nephrocalcinosis, and hypercalciuria. 
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SPECIFIC AIMS 
 
 Little is known about the prevalence and clinical spectrum of 24-hydroxylase 
deficiency, particularly in pediatric patients. Our study aims to determine the prevalence 
and clinical characteristics of pediatric patients with laboratory findings suggestive of 24-
hydroxylase deficiency, specifically high-normal or high serum 1,25(OH)2D. 
 Through a retrospective chart review of pediatric patients at Boston Children’s 
Hospital, we aim to:  
1) Determine the prevalence of elevated 1,25(OH)2D in pediatric patients with 
nephrolithiasis  
2) Compare the clinical outcomes in children with normal (≤ 55 pg/mL) versus 
elevated (> 55 pg/mL) levels of serum 1,25(OH)2D, with specific regard to 
recurrence of nephrolithiasis  
3) Compare the biochemical findings in children with normal versus elevated 
1,25(OH)2D, with specific regard to urine calcium/creatinine ratio. 
 
We hope these studies will provide information that will allow for clinical 
recommendations regarding elevated 1,25(OH)2D and provide the basis for further 
studies of CYP24A1 mutations in pediatric nephrolithiasis and related disorders. 
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PATIENTS AND METHODS 
 
 This retrospective chart review was approved by the Institutional Review Board at 
Boston Children’s Hospital (BCH). Due to the fact that many eligible subjects might not 
be able to be contacted for consent (e.g. deceased, no longer followed in institution), and 
the study involved no more than minimal risk, a waiver of consent was approved. We 
reviewed clinical records from the BCH electronic medical records system between 
January 1, 1990 and October 15, 2014, including clinic notes, laboratory data, and 
radiology reports.  
 
Prevalence Study 
 Using the hospital’s electronic medical records system, we identified all patients 
who were seen in the Stone Clinic program at Boston Children’s Hospital between 
January 10, 2007 and October 15, 2014 who were under 18 years of age at the time of 
symptom onset or initial diagnosis.  
 The following data were recorded for each patient: sex, date of birth, date of onset 
of symptoms or incidental diagnosis, and all 1,25(OH)2D levels that were measured at 
BCH. Where applicable, we used outside medical records that had been uploaded into 
BCH electronic medical records in order to determine the date of onset. Outside 
laboratory results were not included in the study.  
 Patients were grouped based on their highest measured 1,25(OH)2D level: Normal 
(≤55 pg/mL), High-Normal (56-75 pg/mL), or High (>75 pg/mL). Patients who did not 
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have any record of 1,25(OH)2D measurements within the study period were placed into a 
separate group. 
 
Clinical Characteristics Study  
 Patients were eligible who had a diagnosis based on ICD-9 code of calculus of the 
kidney and ureter (592), calculus of lower urinary tract (594), or other disorder of 
calcium metabolism (including nephrocalcinosis or hypercalciuria) (275.49); who were 
under 18 years of age at the time of diagnosis or onset of symptoms; and who had at least 
one recorded laboratory value for 1,25(OH)2D. Potential subjects were identified via 
automated query of the electronic medical records, and eligibility was confirmed by 
review of the medical records. Exclusion criteria included a diagnosis of 
hypoparathyroidism (ICD-9 252.1) or premature birth at less than 31 weeks gestation. 
Hypoparathyroidism is often treated with calcium and vitamin D, which would affect 
laboratory values for our review. Premature infants are often treated with vitamin D to 
prevent osteopenia and furosemide to aid in breathing. Furosemide treatment has a 
known association with hypercalciuria and nephrolithiasis.   
 Our initial cohort consisted of 52 patients who met the study criteria and were 
enrolled in a related genetics study in the Department of Nephrology at BCH. We 
expanded our cohort based on the results of our i2b2 queries. Priority was placed on 
patients who had been seen in Stone Clinic and had a diagnosis that was confirmed by 
radiology studies or urine solute analysis.  
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 All collected data were stored in the REDCap secure data system at BCH. Each 
patient was de-identified and assigned a study number, and study ID linkages were 
maintained separately from data collection. Patient information was obtained from the 
BCH electronic medical record system, including laboratory test results, radiology 
studies, and clinic notes. Outside medical records were included in our review only when 
available through the BCH electronic medical record system. Due to the retrospective 
nature of the study, no additional tests or records were requested to complete missing 
data.  
 Data collected included demographic information; diagnosis of nephrolithiasis, 
nephrocalcinosis, or hypercalciuria; family history of these conditions; treatments 
administered; and radiographic findings from ultrasound or CT. Laboratory data included 
serum calcium, phosphate, PTH, 1,25(OH)2D, and 25(OH)D, and urine calcium and 
creatinine. Urine calcium/creatinine ratio was calculated exclusively for samples obtained 
prior to the initiation of treatment. We preferentially used 24-hour urine samples if 
available within 6 months of the reference serum date. Otherwise, a spot urine sample 
was used. Twenty-four hour urine studies were available for 46 of the 83 patients who 
were included in statistical analysis.  
 
Statistical Analysis 
 Our primary outcomes were prevalence of elevated 1,25(OH)2D in pediatric 
patients with nephrolithiasis; recurrence of nephrolithiasis in patients with normal versus 
elevated 1,25(OH)2D; and urine Ca/Cr ratios in patients with normal versus elevated 
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1,25(OH)2D. Patients were grouped based on their highest measured 1,25(OH)2D level. 
We defined elevated 1,25(OH)2D as levels in the upper third of normal range or higher 
(>55 pg/mL), while patients with 1,25(OH)2D ≤55 pg/mL were defined as normal.  
 Recurrence of nephrolithiasis was defined as the formation of a new stone after an 
initial diagnosis of nephrolithiasis. Patients who had no history of nephrolithiasis were 
excluded from the analysis of recurrence. Recurrence in patients with normal versus 
elevated 1,25(OH)2D was analyzed using the chi squared test. Logistic regression was 
used to analyze the relationship between 1,25(OH)2D levels and recurrence of 
nephrolithiasis.    
 We conducted univariate logistic regression analyses to identify additional 
variables that were associated with recurrence of nephrolithiasis. Significant predictive 
variables by univariate analysis were included in a multivariate logistic regression 
analysis to determine which variables were independent predictors of recurrence of 
nephrolithiasis.  
Student’s t-test was used to compare the mean urine Ca/Cr ratio in patients with 
normal versus elevated 1,25(OH)2D. The relationship between 1,25(OH)2D as a 
continuous variable and urine Ca/Cr ratio was further analyzed via linear regression.  
We conducted univariate linear regression analyses to determine whether other 
variables were associated with urine Ca/Cr ratio. A multivariate model was then 
constructed to identify independent predictors of urine Ca/Cr. Because of the known 
association between age and urine Ca/Cr ratio, a multivariate linear regression was 
conducted to determine whether there was a confounding effect.  
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 For secondary outcomes, we analyzed the relationship between 1,25(OH)2D 
levels and age of onset, family history, 25(OH)D, PTH, serum calcium, serum 
phosphorus, and urine calcium mg/kg/day. Patients with missing values were excluded 
from the associated analysis. Continuous outcomes were analyzed by Student’s t-test, and 
categorical variables were analyzed by chi squared test.  
  
Changes to Planned Methods: 
 Based on the results of our regression analyses, we conducted post-hoc analysis of 
urine Ca/Cr ratio and recurrence of nephrolithiasis in patients with normal versus high 
1,25(OH)2D, defined as above the upper limit of normal 1,25(OH)2D (>75 pg/mL). We 
therefore conducted new analyses to compare urine Ca/Cr ratios and recurrence rates 
between patients with 1,25(OH)2D levels ≤75 pg/mL versus 1,25(OH)2D levels >75 
pg/mL. As in the prior analysis, urine Ca/Cr ratio was analyzed by Student’s t-test, and 
recurrence of nephrolithiasis was analyzed by chi squared test.   
 Many of the patients included in our study were also enrolled in a genetic study 
analyzing the frequency of CYP24A1 mutations in pediatric patients with nephrolithiasis, 
nephrocalcinosis, or hypercalciuria. We had hoped to received genetic results from this 
study in order to analyze and describe the clinical presentation of patients with an 
identified mutation in CYP24A1. Unfortunately, the genetic testing was not completed in 
time for submission and so could not be included in our analysis.  
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RESULTS 
Prevalence of Elevated 1,25(OH)2D in Pediatric Nephrolithiasis 
 We identified a total of 435 patients who were under 18 years old at the time of 
initial presentation with nephrolithiasis. 346 of these patients had at least one recorded 
measurement of 1,25(OH)2D (Table 1). The prevalence of high 1,25(OH)2D was 28.9%, 
and the prevalence of high-normal 1,25(OH)2D was 34.7%.  
 Overall, more girls than boys were evaluated in Stone Clinic. 28.8% of girls had 
high 1,25(OH)2D and 37.2% had high-normal 1,25(OH)2D compared to 29.0% and 
30.5%, respectively, in boys. However, there was no statistically significant relationship 
between sex and 1,25(OH)2D levels (p = .37).  
 
Table 1. Vitamin D (1,25(OH)2D) levels in pediatric patients with nephrolithiasis Subjects 
were seen in Stone Clinic at Boston Children’s Hospital and are classified by their highest 
1,25(OH)2D level: Normal (≤55 pg/mL), High-Normal (56-75 pg/mL), High (>75 pg/mL) 
 Male Female Total 
Normal 1,25(OH)2D 53 73 126 (36.4%) 
High-Normal 1,25(OH)2D 40 80 120 (34.7%) 
High 1,25(OH)2D 38 62 100 (28.9%) 
Total 131 215 346 
 
 
Clinical Characteristics  
 We identified 83 children with nephrolithiasis, nephrocalcinosis, or hypercalciuria 
who fulfilled the criteria for inclusion in the study (Table 2). Seventy-five of these 
children were diagnosed with nephrolithiasis, 12 with nephrocalcinosis, and 34 with 
hypercalciuria. There were more girls than boys (49 vs. 34). Forty-seven reported a 
family history of nephrolithiasis, nephrocalcinosis, or hypercalciuria; four were adopted 
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and had an unknown family history. Twelve patients reported the use of vitamin D 
supplementation prior to presentation.  
 
Table 2. Demographics and clinical characteristics of patients with normal (≤55 pg/mL) 
versus elevated (>55 pg/mL) 1,25(OH)2D 
 All Patients Normal 1,25(OH)2D 
Elevated 
1,25(OH)2D p 
Group total 83 40 43 - 
Sex M/F 34/49 18/21 16/28 .38 
Mean (±SEM) age at presentation 
(years) 10.04 (± 0.56) 11.60 (± 0.77) 8.60 (± 0.77) .01 
Age group 
     0-4.9 
     5-9.9 
     10-14.9 
     15-18 
 
18 
21 
24 
20 
 
6 
7 
13 
13 
 
12 
14 
11 
7 
.111 
Diagnosis of nephrolithiasis,  
N (%) 75 (90.3) 38 (95.0) 37 (86.0) .27 
Recurrence of nephrolithiasis 34 9 25 <.001 
Diagnosis of nephrocalcinosis,  
N (%) 12 (14.5) 2 (5.0) 10 (23.2) .03 
Diagnosis of hypercalciuria,  
N (%) 34 (40.9) 12 (30.0) 23 (53.5) .05 
Family history*, N (%) 47 (56.6) 20 (50.0) 27 (62.8) .37 
Vitamin D supplementation 12 7 5 .45 
*Family history of nephrolithiasis, nephrocalcinosis, or hypercalciuria  
 
 The 83 children in our cohort have been followed for a mean (±SEM) of 3.4 
(±0.3) years, with a range of 0 to 14.6 years. Children with elevated 1,25(OH)2D were 
younger at presentation (8.60 ± 0.77 vs. 11.60 ± 0.77 years, p = .01), and were more 
likely to have a diagnosis of nephrocalcinosis (23.2% vs. 5.0%, p = .03) or hypercalciuria 
(53.3% vs. 30.0%, p = .05). There was no significant difference in the diagnosis of 
nephrolithiasis between the two groups.  
 Among the 75 patients who were diagnosed with nephrolithiasis, 34 (45.3%) had 
at least one new stone during follow-up. There was a significantly higher rate of 
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recurrence among patients with elevated 1,25(OH)2D compared to normal 1,25(OH)2D (p 
< .001). Univariate logistic regression demonstrated that 1,25(OH)2D levels were a 
significant predictor of recurrence of nephrolithiasis (Odds Ratio (OR) = 1.025, 
Nagelkerke R2 = 0.135, p = .01).   
 We also investigated additional clinical variables associated with recurrence of 
nephrolithiasis (Table 3). Univariate binary logistic regression analysis demonstrated that 
serum calcium (p = .01) and PTH (p = .04) were significant predictors of recurrence of 
nephrolithiasis in addition to 1,25(OH)2D; however, in multivariate analysis, only 
1,25(OH)2D (OR = 1.02, p = .04) and serum calcium (OR = 5.26, p = .04) remained 
independent predictors of nephrolithiasis.  
 
Table 3. Analysis of clinical variables predicting recurrence of nephrolithiasis  
 Univariate Analysis Multivariate Analysis 
 Odds Ratio ± SEM R2 p Odds Ratio ± SEM R2 p 
1,25(OH)2D (pg/mL) 1.03 ± 0.01 0.009 .01 1.02 ± 0.01 0.269 .03 
25(OH)D (ng/mL) 1.04 ± 0.02 0.062 .07 0.98 ± 0.03 0.280 .98 
PTH (pg/mL) 0.96 ± 0.02 0.083 .04 0.97 ± 0.02 0.298 .22 
Serum Calcium 
(mg/dL) 7.24 ± 2.83 0.174 .01 7.09 ± 2.81 0.269 .01 
Serum Phosphorus 
(mg/dL) 1.16 ± 0.30 0.004 .69 - - - 
Age of Onset 0.97 ± 0.05 0.010 .46 - - - 
Family history 1.50 ± 0.46 0.013 .40 - - - 
Urine Ca/Cr ratio 
(mg/mg) 2.55 ± 1.15 0.011 .44 - - - 
Urine Calcium 
(mg/kg/day) 1.09 ± 0.16 0.007 .64 - - - 
 
 We did not find a statistically significant difference in urine Ca/Cr ratio between 
patients with normal versus elevated 1,25(OH)2D (0.020 ± 0.03 vs. 0.27 ± 0.04 mg/mg,   
p = .17) (Table 4). However, a scatterplot of 1,25(OH)2D vs. urine Ca/Cr ratio suggested 
a positive correlation. Linear regression analysis suggested that a statistically significant 
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proportion of the variation in urine Ca/Cr ratios was predicted by 1,25(OH)2D (β = 0.002 
± 0.001, R2 = 0.11, p = .002). Because of this statistically significant relationship between 
1,25(OH)2D level and urine Ca/Cr ratio, we conducted a post-hoc t-test of urine Ca/Cr 
ratio in patients with normal versus high 1,25(OH)2D, with a cut-off of 75 pg/mL 
between these two groups. Patients with 1,25(OH)2D levels >75 pg/mL had higher urine 
Ca/Cr ratios than patients with 1,25(OH)2D levels ≤75 pg/mL (0.33 ± 0.06 vs. 0.19 ± 
0.02 mg/mg, p = .04).    
 
Table 4. Laboratory data Laboratory serum values and urine solute analyses for patients with normal 
(≤55 pg/mL) versus elevated (>55 pg/mL) 1,25(OH)2D. Variations in group totals (N) reflect the 
absence of associated tests for a portion of our cohort.  
 All Patients Normal 1,25(OH)2D 
Elevated 
1,25(OH)2D  
 N Mean ± SEM N Mean ± SEM N Mean ± SEM p 
Highest 1,25(OH)2D 
(pg/mL) 83 68.4 ± 3.7 40 43.5 ± 1.2 43 91.6 ± 4.6 - 
Urine Ca/Cr Ratio 
(mg/mg) 83 0.24 ± 0.02 40 0.20 ± 0.03 43 0.27 ± 0.04 .17 
25(OH)D (ng/mL) 83 29.4 ± 1.3 40 23.8 ± 1.4 43 34.7 ± 1.8 < .001 
PTH (pg/mL) 83 27.2 ± 1.7 40 30.8 ± 2.4 43 23.8 ± 2.2 .04 
Serum Calcium 
(mg/dL) 67 9.9 ± 0.1 32 9.8 ± 0.8 35 9.9 ± 0.1 .23 
Serum Phosphorus 
(mg/dL) 63 4.1 ± 0.1 32 4.1 ± 0.1 31 4.1 ± 0.2 .82 
Urine Calcium 
(mg/kg/day) 46 3.40 ± 0.28 26 2.96 ± 0.32 20 3.98 ± 0.47 0.07 
 
   
 Because urine calcium excretion is likely to be a risk factor for recurrence of 
nephrolithiasis and exacerbation of nephrocalcinosis, we sought to determine what 
clinical variables were predictive of elevated urine Ca/Cr ratio in our cohort (Table 5). 
Univariate analysis demonstrated that 1,25(OH)2D (p = .002), 25(OH)D (p = .04) and 
serum calcium (p < .001) were significantly associated with urine Ca/Cr ratio. 
Subsequent multivariate linear regression showed that both 1,25(OH)2D (β = 0.001 ± 
 32 
.001, R2 = 0.546, p = .01) and serum calcium (β = 0.255 ± 0.037, R2 = 0.546, p < .001) 
were independent predictors of urine Ca/Cr ratio.  
 
Table 5. Analysis of clinical variables predicting urine Ca/Cr ratio 
 Univariate Analysis Multivariate Analysis 
 Beta ± SEM R2 p Beta ± SEM R2 p 
1,25(OH)2D (pg/mL) 0.002 ± 0.001 0.114 .002 0.001 ± 0.001 0.546 .01 
25(OH)D (ng/mL) 0.004 ± 0.002 0.039 .04 -0.001 ± 0.002 0.555 .77 
PTH (pg/mL) -0.002 ± 0.002 0.014 0.28 - - - 
Serum Calcium (mg/dL) 0.290 ± 0.036 0.496 < .001 0.255 ± 0.037 0.546 < .001 
Serum Phosphorus 
(mg/dL) 0.024 ± 0.037 0.007 .52 - - - 
Age of Onset -0.017 ± 0.004 0.149 < .001 -0.004 ± 0.004 0.555 .28 
Family history -0.029 ± 0.053 0.004 .58 - - - 
 
Additionally, univariate linear regression showed a significant relationship 
between age at onset and urine Ca/Cr ratio (p < .001), although the significance was lost 
in multivariate analysis. There is a known relationship between younger age and higher 
urine Ca/Cr ratio. Because the date of onset was not necessarily associated with the date 
on which the urine solute analysis was conducted, we removed all subjects in whom the 
difference between the two dates was six months or greater, after which 60 subjects 
remained. A linear regression analysis was conducted to determine an interaction effect 
between 1,25(OH)2D and age on urine Ca/Cr ratio among the 60 eligible subjects and 
was found to be significant (β = -0.356, R2 = 0.127, p = .005), suggesting that age may 
confound the effect of 1,25(OH)2D on urine Ca/Cr ratio. In a multivariate analysis of the 
effect of both 1,25(OH)2D and age on urine Ca/Cr ratio, both variables remained 
independently associated with urine Ca/Cr ratio, demonstrating that both variables are 
independent predictors.   
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DISCUSSION 
 
 CYP24A1 mutations have been shown to have a wide range of clinical 
phenotypes. In all reported cases, patients have had high-normal or high 1,25(OH)2D. 
Symptoms were related to abnormal calcium metabolism and included hypercalcemia, 
nephrolithiasis, and nephrocalcinosis. In this single-center retrospective study, we sought 
to determine the prevalence and clinical characteristics of patients with findings 
suggestive of CYP24A1 mutations, specifically high-normal or high 1,25(OH)2D and a 
diagnosis of nephrolithiasis, nephrocalcinosis, or hypercalciuria. We determined the 
prevalence of elevated 1,25(OH)2D in pediatric kidney stone patients and found a 
positive association between elevated 1,25(OH)2D and recurrence of nephrolithiasis. We 
found no statistically significant difference in mean urine calcium/creatinine ratio 
between our two study groups.  
  We identified 346 children from Boston Children’s Hospital Stone Clinic with 
nephrolithiasis in whom a serum assay of 1,25(OH)2D was conducted. We found that 100 
(28.9%) of the children had high 1,25(OH)2D, exceeding 75 pg/mL, and an additional 
120 (34.7%) of the children had high-normal 1,25(OH)2D between 56 and 75 pg/mL. To 
date, there have been no prevalence studies of elevated serum 1,25(OH)2D in the general 
pediatric population or among children with nephrolithiasis. Normal clinical ranges 
should encompass 95% of the general population, so only 2.5% of the general healthy 
population should have 1,25(OH)2D levels greater than normal. Our study provides a 
novel finding of the prevalence of elevated 1,25(OH)2D among pediatric patients with 
nephrolithiasis. Furthermore, because almost one-third of patients with nephrolithiasis 
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had 1,25(OH)2D levels above the normal clinical range, this suggests that 1,25(OH)2D 
plays some role in the disease process.  
Our analysis demonstrates that children with 1,25(OH)2D >55 pg/mL have a 
higher rate of recurrence of nephrolithiasis than children with lower 1,25(OH)2D levels. 
This is a novel finding, as no other studies have evaluated the effect of 1,25(OH)2D on 
recurrence of nephrolithiasis. This finding is clinically important, as it aids in 
understanding the prognosis of children with nephrolithiasis and allows for 
recommendations regarding treatment and follow-up. Importantly, our finding can aid 
clinicians in determining the necessity for treatments that reduce the likelihood of stone 
formation, such as the use of thiazide or amiloride diuretics, magnesium, and citrate in 
patients with no other identified cause for nephrolithiasis.  
Another important clinical finding was the association of elevated 1,25(OH)2D 
with age of onset in our cohort. In the adult population, nephrolithiasis is positively 
correlated with increasing age (Scales et al., 2012). In our study, the mean age of onset 
was 3.0 years younger in patients with 1,25(OH)2D levels >55 pg/mL than in patients 
with lower 1,25(OH)2D. This may reflect a general phenomenon toward higher 
1,25(OH)2D levels with decreasing age, or the fact that younger patients are more likely 
than older patients to have a defect in vitamin D metabolism underlying their diagnosis of 
nephrolithiasis, nephrocalcinosis, or hypercalciuria.   
 Contrary to our hypothesis, we found only a weak relationship between 
1,25(OH)2D levels and urine Ca/Cr ratio. We found no statistically significant difference 
in mean urine Ca/Cr ratio in patients with 1,25(OH)2D levels >55 pg/mL versus 
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1,25(OH)2D ≤ 55 pg/mL. However, linear regression demonstrated a weak but 
statistically significant effect of 1,25(OH)2D on urine Ca/Cr ratio. A post-hoc analysis 
showed a significantly higher mean urine Ca/Cr ratio in patients with 1,25(OH)2D >75 
pg/mL (the assay upper limit of normal) than in patients with normal 1,25(OH)2D (≤75 
pg/mL). This suggests an alternative hypothesis of a threshold effect in which patients 
with 1,25(OH)2D levels above clinical normal limits had higher urine Ca/Cr ratios than 
patients with 1,25(OH)2D within clinical normal limits.  
One difficulty in considering the effects of other factors on urine Ca/Cr ratio was 
the effect of age. It is well reported that younger age is associated with higher urine 
Ca/Cr ratios in children. In children under 2 years of age, a normal ratio is 0.6-0.8 mg/mg 
versus 0.2 mg/mg in children over 2 years. We did find that a younger age of onset was 
associated with both higher 1,25(OH)2D and higher urine Ca/Cr ratio. Analysis of the 
interaction variable suggested that 1,25(OH)2D level modifies the effect of age on urine 
Ca/Cr ratio, or vice-versa. However, both variables remained significant in a multivariate 
model, demonstrating that both 1,25(OH)2D levels and age are also independent 
predictors of urine Ca/Cr ratio.  
 In considering the effects of phosphorus and PTH, it is important to note that no 
patients had a phosphorus deficiency or hyperparathyroidism. Serum phosphorus levels 
are largely dependent on diet and, because samples were not obtained at a standard time 
relative to meals, were therefore highly variable between patients. Phosphorus deficiency 
drives the production of 1,25(OH)2D. No association was found between 1,25(OH)2D 
level and serum phosphorus. Patients with elevated 1,25(OH)2D had lower serum PTH 
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than patients with normal 1,25(OH)2D, which is consistent with suppression of PTH by 
an abnormality in vitamin D or calcium metabolism, not with increased activation of 
vitamin D by excess PTH action as might be seen in mild primary hyperparathyroidism.   
 Forty-seven (56.6%) children in our study had family members with a history of 
nephrolithiasis, nephrocalcinosis, or hypercalciuria (4 were adopted). This number is 
higher than the 40-45% reported in other studies (Milliner, 2009; Nesterova et al., 2013). 
It is possible the patients presenting with these conditions in childhood rather than 
adulthood are more likely to have a familial cause as opposed to an environmental one. 
However, we found no significant difference in the frequency of family history between 
patients with normal or elevated 1,25(OH)2D. Additionally, family history showed no 
correlation with urine Ca/Cr ratio or recurrence of nephrolithiasis.   
 
Study Limitations 
 Due to the retrospective nature of our study, many eligible patients did not have 
sufficient data for analysis. On chart review, we found that many patients lacked the 
necessary studies for comparative analyses, particularly pre-treatment urine solute 
analyses. Especially among patients who transferred from another provider, many urine 
solute analyses were only conducted after the initiation of treatment, thus excluding them 
from our analyses of urine calcium excretion.  
 Our prevalence analysis was affected by the number of patients in whom no assay 
of 1,25(OH)2D was conducted. In addition to the 346 children in whom a serum assay of 
1,25(OH)2D was conducted, there were 89 children for whom no record of 1,25(OH)2D 
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levels was available. It is possible that 1,25(OH)2D levels are checked more frequently in 
patients in whom the clinician has a high suspicion, leading to selection bias and 
overestimation of the prevalence of elevated 1,25(OH)2D levels in our cohort. We would 
therefore suggest future prospective studies to better determine the prevalence of elevated 
1,25(OH)2D among children with nephrolithiasis.  
Our study inclusion criteria did not define a minimum follow-up period or require 
that a patient have any follow-up after the initial visit, which limited our ability to detect 
recurrence of nephrolithiasis. Although this limitation exists, we believe its effect should 
be small because nephrolithiasis is typically symptomatic and often painful, and therefore 
patients experiencing recurrent symptoms are likely to present for medical care in the 
emergency setting or in clinic follow-up. In addition, loss to follow-up in unlikely to be 
related to 1,25(OH)2D level, so this limitation is unlikely to affect the finding that 
elevated 1,25(OH)2D is associated with recurrence of nephrolithiasis.  
 Ideally, 24-hour urine studies would have been used exclusively to determine 
urine Ca/Cr ratios in all patients. However, completing a 24-hour urine study at home 
requires patients to be toilet-trained (or use a catheter) and not to have nighttime enuresis, 
which would exclude many of the younger patients from our study. Additionally, not all 
patients complete a 24-hour urine study when advised by their doctors, and so availability 
of these studies was highly dependent on patient compliance. In several of our patients, 
no 24-hour urine study was available, and so a random urine solute analysis was used 
instead. These may be less accurate, which would affect our analysis of 1,25(OH)2D and 
urine calcium/creatinine ratios. We tested the extent of this inaccuracy and found no 
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statistically significant difference in the means between 24-hour urines and random urine 
solute analysis.  
  
Vitamin D supplementation 
 Nephrolithiasis is not an absolute contraindication to vitamin D supplementation. 
A study by Leaf et al. (2012) of vitamin D repletion in kidney stone formers found no 
significant difference in mean urinary calcium excretion before and after vitamin D 
repletion. In otherwise healthy children, vitamin D supplementation via fortified foods or 
other-the-counter supplements should not be sufficient to cause elevated 1,25(OH)2D, 
due to the tight control of the activation process. Additionally, adults with osteoporosis 
and a history of nephrolithiasis have a better outcome when receiving the RDA of 
vitamin D and calcium in conjunction with treatment for hypercalciuria. 
 In our study, 7 out of 40 children with normal 1,25(OH)2D (17.5%) and 5 out of 
43 children with elevated 1,25(OH)2D (11.6%) reported the use of vitamin D 
supplementation, with no significant difference between the two groups. Only 3 children 
(2 normal, 1 high) reported the use pharmaceutical vitamin D supplementation at the time 
of their highest 1,25(OH)2D level. None of these patients had a laboratory measurement 
of 1,25(OH)2D when they were not using vitamin D supplementation, so it was not 
possible to make a comparative analysis.  
 The appropriate levels and the benefits of vitamin D supplementation remain a 
highly debated topic among health professionals. The IOM finds that a serum 25(OH)D 
level of 20 ng/mL is sufficient to meet the needs of 97.5% of the population across all age 
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groups regardless of geographic locations and advises an RDA of 600 IU for children and 
adults through 70 years of age (Institute of Medicine, 2011). It is possible to meet this 
requirement without pharmaceutical supplementation. In the United States, milk is 
fortified on a voluntary basis with 400 IU per quart (Institute of Medicine, 2011). Other 
fortified food products include soy milk, orange juice, yogurt, and cereal (Manson & 
Bassuk, 2015).  Vitamin D is also found naturally in fatty fish, fish liver oil, and egg 
yolks. In addition, humans are able make vitamin D via sunlight exposure, although this 
is reduced with the use of sunscreen. In many cases, it is possible to obtain the RDA of 
vitamin D through dietary means alone and without the need for vitamin D pills. 
 In all cases, the benefits of treatment must be balanced with associated risks, and 
some patients may be at higher risk than others for adverse effects of vitamin D 
supplementation. In particular, vitamin D supplementation may put patients with 
CYP24A1 mutations at risk for toxicity. Schlingmann et al. (2011) identified four patients 
with IIH who became symptomatic only after vitamin D pulse therapy. Figueres et al. 
(2015) found that prolonged sunlight exposure correlated with increases in serum calcium 
and urine calcium among 7 patients with CYP24A1 mutations. Consideration of 
CYP24A1 mutations is therefore important when considering vitamin D repletion among 
children with nephrolithiasis, nephrocalcinosis, or hypercalciuria. Genetic testing can 
give conclusive evidence of CYP24A1 mutations but is not a viable option for all patients, 
and there is currently no enzyme assay to determine the functionality of CYP24A1. 
Therefore, other clinical methods of assessing for this deficiency are necessary to guide 
management decisions. We recommend serum assays of 1,25(OH)2D and PTH and 24-
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hour urine solute analysis prior to and after initiation of vitamin D repletion in children 
with nephrolithiasis and related disorders in order to identify patients who may have 
CYP24A1 mutations and be at risk of worsening symptoms. It is important for clinicians 
to counsel patients in achieving the RDA of vitamin D without resulting in elevated 
vitamin D and recurrence of nephrolithiasis, especially for patients in whom the normal 
regulatory mechanisms do not function properly.  
 
Future Studies 
 Understanding of the prevalence and clinical characteristics of elevated 
1,25(OH)2D would be greatly enhanced by a multi-center prospective study. Future 
studies should include measures of 1,25(OH)2D and 24-hour urine studies at the time of 
presentation with nephrolithiasis, nephrocalcinosis, or hypercalciuria and prior to the 
initiation of treatment. Furthermore, genetic analysis would help to determine the 
prevalence of CYP24A1 mutations among pediatric patients with nephrolithiasis and 
related disorders and assess the validity of elevated 1,25(OH)2D as a primary 
consideration for CYP24A1 mutations. An obstacle in determining the prevalence and 
clinical manifestations of CYP24A1 mutations is that there is currently no commercially-
available method to measure CYP24A1 activity. As genetic testing of CYP24A1 becomes 
more widely available in the clinical setting, it will provide a better clinical understanding 
of CYP24A1 mutations. 
 Additionally, future studies are needed to determine the impact of nutritional 
vitamin D supplementation in these at-risk populations. Specifically, studies are needed 
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to determine the risk of increased 1,25(OH)2D and nephrolithiasis in conjunction with 
nutritional vitamin D supplementation in patients with CYP24A1 mutations.  
 
Conclusion 
 Mutations in CYP24A1 are associated with elevated 1,25(OH)2D. In this study, we 
found that patients with 1,25(OH)2D levels in the upper third of the normal range or 
higher (>55 pg/mL) were statistically younger at onset of nephrolithiasis, 
nephrocalcinosis, or hypercalciuria and were more likely to have recurrent nephrolithiasis 
than those with lower 1,25(OH)2D levels. Additionally, we found that they had higher 
urine calcium/creatinine ratios, although the difference only became significant at 
1,25(OH)2D levels above the upper limit of normal (>75 pg/mL). Although CYP24A1 
mutations do not account for the majority of cases of elevated 1,25(OH)2D, we hope that 
this study will raise awareness of the clinical significance of elevated 1,25(OH)2D and 
prompt further investigation into its underlying cause among pediatric patients with 
nephrolithiasis and related disorders. 
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